Borba EF et al. (2006) Mycophenolate mofetil is effective in reducing lupus glomerulonephritis proteinuria. Rheumatol Int 26: 1078–1083
The optimum treatment for patients with membranous lupus nephritis is uncertain. Several therapeutic regimens have been suggested, including corticosteroids plus cyclophosphamide or chlorambucil; however, these regimens are associated with serious side effects. Mycophenolate mofetil reduces proteinuria in animal models of membranous nephropathy; Borba and colleagues, therefore, assessed the efficacy and tolerability of mycophenolate mofetil treatment of persistent proteinuria in patients with systemic lupus erythematosus (SLE).
In this 18-month pilot study, 20 patients with SLE and persistent isolated severe proteinuria or proteinuric flare (12 of whom had biopsy-proven membranous glomerulonephritis) received open-label mycophenolate mofetil 1.5 g daily for 1 month, escalated to a maximum of 3 g daily or until proteinuria decreased. At enrollment, all patients were taking antimalarial agents and angiotensin-converting-enzyme inhibitors, which were continued throughout the study. Immunosuppressive therapies other than prednisone were discontinued.
Mycophenolate mofetil was well tolerated and associated with few side effects. All patients achieved a partial response (a decrease in proteinuria of ≥50% from baseline) after a mean of 8.2 ± 3.3 months of 2.3 ± 0.5 g mycophenolate mofetil daily. An initial increase of proteinuria was observed in three patients at 4.6 ± 1.5 months; these patients responded to an intravenous dose of methylprednisolone and an increased dose of mycophenolate mofetil. Proteinuria had normalized (<0.3 g per 24 h) in 11 patients at 12.2 ± 3.0 months.
The authors concluded that mycophenolate mofetil could be an effective therapy for patients with SLE who experience persistent proteinuria. Prospective, randomized, controlled trials are warranted.
Rights and permissions
About this article
Cite this article
Mycophenolate mofetil is a promising treatment for persistent proteinuria in SLE. Nat Rev Rheumatol 3, 9 (2007). https://doi.org/10.1038/ncprheum0369
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0369